CPNP Online Resources

CPNP members have provided a number of valuable informational resources for your review. If you see something missing, feel free to suggest a new resource.

Press Releases

College of Psychiatric and Neurologic Pharmacists Announces Slate for 2015-2017 Board Officer Election

The College of Psychiatric and Neurologic Pharmacists (CPNP) Nominations Committee is pleased to announce the consideration of over 25 individuals for 3 positions on the 2015-2017 CPNP Board of Directors. Now narrowed to a slate of 6 candidates, CPNP active members will have the opportunity to select 1 individual to serve in each position. Elections will take place online at from November 3-21, 2014. A link to the voting center will be sent via email to all active members on November 3.

Candidates Include:

President-Elect Candidates:

The College of Psychiatric and Neurologic Pharmacists (CPNP) Announces the Recipient of the 2015 Judith J. Saklad Memorial Award

The College of Psychiatric and Neurologic Pharmacists (CPNP) is pleased to announce the recipient of the 2015 Judith J. Saklad Memorial Award, Carla Cobb, PharmD, BCPP. Dr. Cobb is a Psychiatric Pharmacist at RiverStone Health Clinic in Billings, Montana.

CPNP Generates Buzz at the NAMI Annual Meeting

The National Alliance on Mental Illness (NAMI) held their national convention in Washington, D.C., September 3-6. The popular CPNP “Ask the Psychiatric Pharmacist” booth received special mention in NAMI’s post-convention video update from Mary Giliberti, NAMI Executive Director.

In the recorded interview (timestamp 2:25-3:25), CPNP member Judy Curtis explains who CPNP is and what neuropsychiatric pharmacists contribute to patient care. CPNP student members Kayla Tegeler and Marcus Ellis, with assistance from Heidi Wehring, PharmD, BCPP, staffed the “Ask the Psychiatric Pharmacist” booth and shared the type of questions they answered at the very popular booth.

CPNP has had a long-lasting relationship with NAMI staffing the Ask the Psycyhiatric Pharmacist booth and providing 2 educational sessions (Medication and Treatment Challenges for the Young Adults and New Psychiatric Medications: Knowledge is Power) as a way to reinforce the important role psychiatric pharmacists can bring to the treatment team. A special thanks to all of the volunteers who represented CPNP and provided valuable services at NAMI 2014: Shelly Spollen, Karen Moeller, Judy Curtis, LaGenia Bailey, Alice Mascialino, Heidi Wehring, Kayla Tegeler, Marcus Ellis, Jerry Overman, and Cassidy Zammit.

Industry News

Torres-Torres R, Sanchez-Dalmau BF. Treatment of acute optic neuritis and vision complaints in multiple sclerosis. Curr Treat Options Neurol. 2015;17(1):328. doi:10.1007/s11940-014-0328-z.
OPINION STATEMENT: Multiple sclerosis is an autoimmune demyelinating disorder of the nervous system, in which almost all patients develop some degree of visual impairment during the disease. Optic neuritis is the most common and known visual affection and may be the initial clinical disease manifestation, but visual complaints can have a wide variety of presentations and some of them can lead to clinical confusion. Most symptoms are the result of acute injury and subsequent axonal loss in the afferent and...
Pérez LP, González RS, Lázaro EB. Treatment of mood disorders in multiple sclerosis. Curr Treat Options Neurol. 2015;17(1):323. doi:10.1007/s11940-014-0323-4.
OPINION STATEMENT: Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system with a significant comorbidity with depressive disorders. Prevalence rates for major depressive disorder (MDD) range from 36 % to 54 % and the rate is around 22 % for adjustment disorders. Selective serotonin reuptake inhibitors (SSRIs) are considered well-tolerated first-line treatment. Tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) are generally reserved for second-line...
Sola-Valls N, Sepúlveda M, Blanco Y, Saiz A. Current role of chemotherapy and bone marrow transplantation in multiple sclerosis. Curr Treat Options Neurol. 2015;17(1):324. doi:10.1007/s11940-014-0324-3.
OPINION STATEMENT: The range of available treatment options for patients with multiple sclerosis (MS) has expanded tremendously in recent years, adding further complexity to the therapeutic decision-making process. The first-generation therapies interferon beta and glatiramer acetate have been safely used for more than 20 years, but are only partially effective. Many of the newly approved MS therapies such as oral agents and monoclonal antibodies are selective immunosuppressants that appear to have...